MEDIVATION, INC. Form 8-K: Current report
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2013-11-13: Form 8-K; Period of report 2013-11-12; Description 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; Details 5.02.
- 2013-11-12: Form 8-K; Period of report 2013-11-12; Description 2.02 Results of Operations and Financial Condition; Details 2.02.
- 2013-10-22: Form 8-K; Period of report 2013-10-22; Description 8.01 Other Events; Details 8.01.
- 2013-10-17: Form 8-K; Period of report 2013-10-10; Description 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year; Details 5.03.
| Filed | Form | Period of report | Description | Details | Document |
|---|---|---|---|---|---|
| 2013-11-13 | 8-K | 2013-11-12 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On November 12, 2013, C. Patrick Machado, Medivation’s Chief Business and Financial Officer, advised Medivation that he has made the decision to retire. | d627728d8k.htm |
| 2013-11-12 | 8-K | 2013-11-12 | 2.02 Results of Operations and Financial Condition | 2.02 On November 12, 2013, Medivation, Inc. (the “Company”) announced its financial results for the third quarter ended September 30, 2013. | d627095d8k.htm |
| 2013-10-22 | 8-K | 2013-10-22 | 8.01 Other Events | 8.01 On October 22, 2013, Medivation, Inc. (the “Company”) and Astellas Pharma Inc. (“Astellas”), the Company’s collaboration partner, issued a joint press release announcing that the Independent Data Monitoring Committee has informed the Company and Astellas of positive results from a planned interim analysis of the global Phase 3 PREVAIL trial of enzalutamide. | d615623d8k.htm |
| 2013-10-17 | 8-K | 2013-10-10 | 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year | 5.03 On October 10, 2013, Medivation, Inc. filed with the Secretary of State of the State of Delaware a Certificate of Elimination eliminating from its Certificate of Incorporation the designation of certain shares of its preferred stock as Series B Preferred Stock; as a result, all shares of preferred stock designated as Series B Preferred Stock were eliminated and returned to the status of authorized but unissued shares of undesignated preferred stock. | d613709d8k.htm |
| 2013-08-08 | 8-K | 2013-08-08 | 2.02 Results of Operations and Financial Condition | 2.02 On August 8, 2013, Medivation, Inc. (the “Company”) announced its financial results for the second quarter ended June 30, 2013. | d581987d8k.htm |
| 2013-08-01 | 8-K | 2013-07-31 | 7.01 Regulation FD Disclosure | 7.01 On August 1, 2013 in Tokyo, Japan (July 31, 2013 in San Francisco, CA), Medivation, Inc.’s alliance partner, Astellas Pharma Inc., reported its financial results for its first fiscal quarter ended June 30, 2013. | d575441d8k.htm |
| 2013-07-01 | 8-K | 2013-06-28 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 5.07 Submission of Matters to a Vote of Security Holders | 5.02 The annual meeting of stockholders of Medivation, Inc. was held on June 28, 2013 (the “Annual Meeting”). 5.07 The Annual Meeting was held on June 28, 2013, and six proposals were submitted to the Medivation stockholders for a vote. | d560456d8k.htm |
| 2013-05-13 | 8-K | 2013-05-12 | 7.01 Regulation FD Disclosure | 7.01 On May 13, 2013, in Tokyo, Japan (May 12, 2013, in San Francisco, CA), Medivation, Inc.’s alliance partner, Astellas Pharma Inc., reported its financial results for its fourth fiscal quarter and year ended March 31, 2013. | d536171d8k.htm |
| 2013-05-09 | 8-K | 2013-05-09 | 2.02 Results of Operations and Financial Condition | 2.02 On May 9, 2013, Medivation, Inc. (the “Company”) announced its financial results for the first quarter ended March 31, 2013. | d536771d8k.htm |
| 2013-04-29 | 8-K | 2013-04-26 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On April 26, 2013, Wendy L. Yarno was elected by the board of directors (the “Board”) of Medivation, Inc. as a member of the Board. | d527525d8k.htm |
| 2013-04-26 | 8-K/A | 2013-04-22 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On April 22, 2013, Dawn Graham was elected by the board of directors (the “Board”) of Medivation, Inc. as a member of the Board. | d527313d8ka.htm |
| 2013-04-26 | 8-K | 2013-04-26 | 8.01 Other Events | 8.01 On April 26, 2013, Medivation, Inc. (the “Company”) and Astellas Pharma Inc. (“Astellas”), the Company’s collaboration partner, issued a joined press release announcing that Astellas Pharma Europe Ltd., the European Headquarters of Astellas, and the Company have received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use, recommending European Commission approval for XTANDI® (enzalutamide) capsules for the treatment of adult men with metastatic castration-resistant prostate cancer whose disease has progressed on or after docetaxel therapy. | d527237d8k.htm |
| 2013-04-23 | 8-K | 2013-04-22 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On April 22, 2013, Dawn Graham was elected by the board of directors (the “Board”) of Medivation, Inc. as a member of the Board. | d524531d8k.htm |
| 2013-04-22 | 8-K | 2013-04-15 | 8.01 Other Events | 8.01 On April 15, 2013, Medivation, Inc. (the “Company”) filed a Notice of Appeal in its ongoing litigation against Aragon Pharmaceuticals, Inc. (“Aragon”). | d524092d8k.htm |
| 2013-04-01 | 8-K | 2013-04-01 | 8.01 Other Events | 8.01 On April 1, 2013, Medivation and Astellas Pharma Inc. issued a press release announcing that the companies have established an updated interim analysis plan for the PREVAIL trial, a global Phase 3 clinical trial evaluating XTANDI® (enzalutamide) capsules in men with metastatic castration-resistant prostate cancer who have not yet received chemotherapy. | d513707d8k.htm |
| 2013-02-28 | 8-K | 2013-02-28 | 2.02 Results of Operations and Financial Condition | 2.02 On February 28, 2013, Medivation, Inc. (the “Company”) announced its financial results for the fourth quarter and fiscal year ended December 31, 2012. | d494225d8k.htm |
| 2013-02-04 | 8-K | 2013-01-31 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On January 31, 2012, Kathryn E. Falberg was elected by the board of directors (the “Board”) of Medivation, Inc. as a member of the Board, and as a member of each of the Audit Committee, the Compensation Committee, and the Nominating and Corporate Governance Committee of the Board. | d479717d8k.htm |
| 2013-02-01 | 8-K | 2013-02-01 | 8.01 Other Events | 8.01 On February 1, 2013 in Tokyo, Japan (January 31, 2013 in San Francisco, CA), Medivation, Inc.’s alliance partner, Astellas Pharma Inc., reported its financial results for its third fiscal quarter ended December 31, 2012. | d477424d8k.htm |